138 related articles for article (PubMed ID: 35727899)
21. Cyclin D1: potential utility as marker for Langerhans cell histiocytosis.
Ben Rejeb S; Charfi L; Sahraoui G; Boujelben N; Mrad K; Doghri R
J Immunoassay Immunochem; 2021 Jul; 42(4):370-379. PubMed ID: 33444078
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in Langerhans cell histiocytosis.
Morimoto A; Oh Y; Shioda Y; Kudo K; Imamura T
Pediatr Int; 2014 Aug; 56(4):451-61. PubMed ID: 24840547
[TBL] [Abstract][Full Text] [Related]
23. Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis.
Jouenne F; Benattia A; Tazi A
Curr Opin Oncol; 2021 Mar; 33(2):101-109. PubMed ID: 33315630
[TBL] [Abstract][Full Text] [Related]
24. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside.
Allen CE; Flores R; Rauch R; Dauser R; Murray JC; Puccetti D; Hsu DA; Sondel P; Hetherington M; Goldman S; McClain KL
Pediatr Blood Cancer; 2010 Mar; 54(3):416-23. PubMed ID: 19908293
[TBL] [Abstract][Full Text] [Related]
25. Recognition and treatment of concurrent active and neurodegenerative langerhans cell histiocytosis: a case report.
Ehrhardt MJ; Karst J; Donohoue PA; Maheshwari M; McClain KL; Bingen K; Kelly ME
J Pediatr Hematol Oncol; 2015 Jan; 37(1):e37-40. PubMed ID: 24322503
[TBL] [Abstract][Full Text] [Related]
26. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
27. Remission of Congenital Multi-system Type Langerhans Cell Histiocytosis with Chemotherapy.
Tamefusa K; Ishida H; Washio K; Ishida T; Morita H; Shimada A
Acta Med Okayama; 2019 Feb; 73(1):61-65. PubMed ID: 30820055
[TBL] [Abstract][Full Text] [Related]
28. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
[TBL] [Abstract][Full Text] [Related]
29. Liver involvement in Langerhans cell histiocytosis.
Wong A; Ortiz-Neira CL; Reslan WA; Sharon R; Pinto-Rojas A; Kaura D; Anderson R
Pediatr Radiol; 2006 Oct; 36(10):1105-7. PubMed ID: 16819598
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous Langerhans Cell Histiocytosis Responsive to Topical Nitrogen Mustard.
Bui AN; Puleo AE; Canales AL; Jacobsen ED; LeBoeuf NR
J Drugs Dermatol; 2020 Aug; 19(8):803-805. PubMed ID: 32845598
[TBL] [Abstract][Full Text] [Related]
31. Langerhans Cell Histiocytosis: Emerging Insights and Clinical Implications.
Zinn DJ; Chakraborty R; Allen CE
Oncology (Williston Park); 2016 Feb; 30(2):122-32, 139. PubMed ID: 26888790
[TBL] [Abstract][Full Text] [Related]
32. Early Diagnosis and Monitoring of Neurodegenerative Langerhans Cell Histiocytosis.
Sieni E; Barba C; Mortilla M; Savelli S; Grisotto L; Di Giacomo G; Romano K; Fonda C; Biggeri A; Guerrini R; Aricò M
PLoS One; 2015; 10(7):e0131635. PubMed ID: 26176859
[TBL] [Abstract][Full Text] [Related]
33. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.
Arceci RJ; Allen CE; Dunkel IJ; Jacobsen E; Whitlock J; Vassallo R; Morris SR; Portnoy A; Reedy BA; Smith DA; Noble R; Murnane A; Cornfeld M; Rodriguez-Galindo C; Heaney ML; McClain K; Vaiselbuh S
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27804235
[TBL] [Abstract][Full Text] [Related]
34. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
35. CyclinD1 Is Useful to Differentiate Langerhans Cell Histiocytosis From Reactive Langerhans Cells.
Chatterjee D; Vishwajeet V; Saikia UN; Radotra B; De D; Bansal D
Am J Dermatopathol; 2019 Mar; 41(3):188-192. PubMed ID: 30124506
[TBL] [Abstract][Full Text] [Related]
36. Langerhans Cell Histiocytosis of the Orbit: Spectrum of Clinical and Imaging Findings.
Lakatos K; Sterlich K; Pötschger U; Thiem E; Hutter C; Prosch H; Minkov M
J Pediatr; 2021 Mar; 230():174-181.e1. PubMed ID: 33157073
[TBL] [Abstract][Full Text] [Related]
37. Langerhans cell histiocytosis: old disease new treatment.
Ng-Cheng-Hin B; O'Hanlon-Brown C; Alifrangis C; Waxman J
QJM; 2011 Feb; 104(2):89-96. PubMed ID: 21084318
[TBL] [Abstract][Full Text] [Related]
38. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
[TBL] [Abstract][Full Text] [Related]
39. Langerhans cell histiocytosis: pragmatic empirism on the road to rational cure.
Minkov M
Expert Opin Pharmacother; 2012 Aug; 13(12):1671-3. PubMed ID: 22712720
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical and molecular cytogenetic evaluation of potential targets for tyrosine kinase inhibitors in Langerhans cell histiocytosis.
Caponetti GC; Miranda RN; Althof PA; Dobesh RC; Sanger WG; Medeiros LJ; Greiner TC; Weisenburger DD
Hum Pathol; 2012 Dec; 43(12):2223-8. PubMed ID: 22748304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
